Mobile Site ›

What the FDA Relabeling of Abacavir Means for You and Your Patient

If HSR Symptoms are Present4

Slide 16

November 2008

The abacavir hypersensitivity reaction symptoms can be classified in one of five groups as seen in the top box. If there are two or more symptoms from two groups within six weeks of starting abacavir therapy, then abacavir should be withheld and the provider should offer supportive therapy as clinical necessary.

Skin patch testing, which is actually phenotypic test for abacavir hypersensitivity reaction could be done. If the skin patch test is positive, the patient should not receive abacavir therapy again. However, if the skin patch test is negative, then re-challenge the patient with abacavir therapy in carefully observed hosp setting.

On the other hand, if the patient has only one or no symptoms within six weeks of starting abacavir, then treatment can be continued, but the patient should still be monitored closely for possible delayed occurrence of hypersensitivity reaction.

If HSR Symptoms are Present4


Jump to section: